Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women
Primary Purpose
Hypertension, Postmenopausal Disorder
Status
Completed
Phase
Phase 4
Locations
Cameroon
Study Type
Interventional
Intervention
Calcium Arm
Vitamin D/Calcium
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Blood pressure, Oxidative status
Eligibility Criteria
Inclusion Criteria:
- Post menopausal hypertensive women since 12 months
- On a stable antihypertensive therapies (determined by the investigator) for at least 3 months with no classes changes.
- Before any study-specific procedure, the appropriate written informed consent must be obtained.
Exclusion Criteria:
- Diabetes mellitus or inflammatory diseases
- Hypercalcemia,
- Side effects affecting life quality of patients (determined by the Data Safety Monitoring Board).
- Withdrawal of consent
Sites / Locations
- Yaounde Central Hospital, Cardiology department
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Calcium arm
Vitamin D/Calcium
Arm Description
1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
Outcomes
Primary Outcome Measures
Change in nycthemeral blood pressure profile (mmHg)
Change in nycthemeral blood pressure profile from baseline to week 08. By using Arterial Blood Pressure Monitoring.
Secondary Outcome Measures
Change in serum concentration of oxidant marker: malondialdehyde (micromol/l)
Change in concentration of oxidant marker from baseline to week 8. By spectrophotometer
Full Information
NCT ID
NCT04255992
First Posted
February 3, 2020
Last Updated
February 3, 2020
Sponsor
Yaounde Central Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04255992
Brief Title
Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women
Official Title
Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women in Sub Saharan Africa
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
May 15, 2019 (Actual)
Study Completion Date
May 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Yaounde Central Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study aims to determine the effect of calcium and vitamin D supplementation on oxidative status and blood pressure profile of postmenopausal patients with high blood pressure in Yaoundé, Cameroon.
This study is a double-arm, double-blind, randomized and parallel clinical trial conducted at the Yaoundé Central Hospital
Detailed Description
Aim: to determine and compare the short term effect of calcium and vitamin D supplementation on oxidative status and blood pressure profile of postmenopausal patients with high blood pressure in Yaoundé, Cameroon.
Method: A double-arm, double-blind, randomized and parallel clinical trial conducted at the Yaoundé Central Hospital. Postmenopausal hypertensive blacks women who are taking taking antihypertensives drugs since 12 months,without diabetes mellitus or any inflammatory disease or hypercalcemia, are randomize into 2 groups. Depending on the group, the intervention consisted of the administration of Calcium 1000 mg daily or Vitamin D/Calcium 1000 mg/800 UI daily for 08 weeks. The endpoints were the nycthemeral blood pressure profile, pro oxidant marker (malondialdehyde) and anti-oxidant marker (Ferric reducing antioxidant).
Progress: Recruitment for this study was completed in May 2019 with 22 patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Postmenopausal Disorder
Keywords
Blood pressure, Oxidative status
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
This study is a double blind, randomized, controlled parallel clinical trial conducted at the Yaounde central hospital, Cameroon
Masking
ParticipantInvestigator
Masking Description
The double-blind model is applied to the study. Only the adjudicator, responsible for the distribution of medication knew the different regimes. Calcium and Vitamin D/Calcium were packaged in boxes of identical appearance and labeled for each participant by name and number of the randomization program. The randomization and packaging of the drugs was done by an investigator who had no clinical involvement.
Allocation
Randomized
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Calcium arm
Arm Type
Active Comparator
Arm Description
1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
Arm Title
Vitamin D/Calcium
Arm Type
Active Comparator
Arm Description
1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Calcium Arm
Intervention Description
1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D/Calcium
Intervention Description
1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Primary Outcome Measure Information:
Title
Change in nycthemeral blood pressure profile (mmHg)
Description
Change in nycthemeral blood pressure profile from baseline to week 08. By using Arterial Blood Pressure Monitoring.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change in serum concentration of oxidant marker: malondialdehyde (micromol/l)
Description
Change in concentration of oxidant marker from baseline to week 8. By spectrophotometer
Time Frame
8 weeks
Other Pre-specified Outcome Measures:
Title
Change in serum concentration of anti-oxidant markers: Ferric reducing antioxidant Power (micromol)
Description
Change in concentration of anti oxidant marker from baseline to week 8. By spectrophotometer
Time Frame
8 weeks
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Postmenopausal hypertensive women
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Post menopausal hypertensive women since 12 months
On a stable antihypertensive therapies (determined by the investigator) for at least 3 months with no classes changes.
Before any study-specific procedure, the appropriate written informed consent must be obtained.
Exclusion Criteria:
Diabetes mellitus or inflammatory diseases
Hypercalcemia,
Side effects affecting life quality of patients (determined by the Data Safety Monitoring Board).
Withdrawal of consent
Facility Information:
Facility Name
Yaounde Central Hospital, Cardiology department
City
Yaounde
Country
Cameroon
12. IPD Sharing Statement
Learn more about this trial
Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women
We'll reach out to this number within 24 hrs